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Abstract
Background: GM1 and GM2 gangliosidoses are progressive neurodegenerative lysosomal storage diseases resulting
from the excessive accumulation of GM1 and GM2 gangliosides in the lysosomes, respectively. The diagnosis of
gangliosidosis is carried out based on comprehensive findings using various types of specimens for histological,
ultrastructural, biochemical and genetic analyses. Therefore, the partial absence or lack of specimens might have
resulted in many undiagnosed cases. The aim of the present study was to establish immunohistochemical and
immunofluorescent techniques for the auxiliary diagnosis of canine and feline gangliosidoses, using paraffin-
embedded brain specimens stored for a long period.
Results: Using hematoxylin and eosin staining, cytoplasmic accumulation of pale to eosinophilic granular materials
in swollen neurons was observed in animals previously diagnosed with GM1 or GM2 gangliosidosis. The
immunohistochemical and immunofluorescent techniques developed in this study clearly demonstrated the
accumulated material to be either GM1 or GM2 ganglioside.
Conclusions: Immunohistochemical and immunofluorescent techniques using stored paraffin-embedded brain
specimens are useful for the retrospective diagnosis of GM1 and GM2 gangliosidoses in dogs and cats.
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Background
GM1 and GM2 gangliosidoses are progressive neurode-
generative lysosomal storage diseases resulting mainly
from the excessive accumulation of GM1 and GM2 gan-
gliosides in the lysosomes, respectively [1]. These diseases
are inherited in an autosomal recessive manner and result
in the premature death of affected individuals due to brain
damage with progressive neurological signs. In GM1 gang-
liosidosis, the accumulation of GM1 ganglioside is caused
by an inherited deficiency of the lysosomal acid β-
galactosidase [2]. In GM2 gangliosidosis, the accumulation
of GM2 ganglioside is caused by an inherited deficiency of
the lysosomal acid β-hexosaminidase A or GM2 activator
protein in GM2 gangliosidosis, and the disease is ac-
cordingly categorized into three variants: Tay-Sachs
disease (B variant), Sandhoff disease (0 variant), and
GM2 activator protein deficiency (AB variant) [3].
Gangliosidosis is more likely to occur in many animal
species and breeds compared to other lysosomal
diseases. Naturally occurring GM1 gangliosidosis has
been reported in dogs, including mixed Beagles [4],
English Springer Spaniels [5], Portuguese Water dogs
[6], Alaskan Huskies [7], Shiba Inus [8], and a mixed-
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breed dog [9], and in cats, including Siamese [10, 11],
Korat [12], and several families of domestic cats [13–17].
In addition, GM1 gangliosidosis has been reported in ru-
minants such as Friesian calves [17, 18], Suffolk sheep
[19], Coopworth Romny-cross sheep [20], and Romny
sheep [21], and in wild species such as American black
bears [22] and emus [23]. Naturally occurring GM2
gangliosidosis has been reported in dogs, including
German Shorthair Pointers [24], Japanese Spaniels
(Chins) [25, 26], a Golden Retriever [27], Toy Poodles
[28], and mixed-breed dogs [29, 30], and in cats, includ-
ing Korat [31], European Burmese [32], and several fam-
ilies of domestic cats [33–35]. In addition, GM2
gangliosidosis has been reported in Yorkshire pigs [36],
Jacob sheep [37], a rabbit [38], Muntjak deer [39], and
American flamingos [40].
The diagnosis of GM1 and GM2 gangliosidoses is car-
ried out based on comprehensive findings, which include
clinical, biochemical, histopathological, and genetic find-
ings using various types of specimens [2, 3]. The clinical
findings are progressive neurological, motor, and visual
dysfunctions, but they are not specific to these diseases
[41]. The biochemical findings include the cerebral accu-
mulation of specific glycoconjugates and deficiency of spe-
cific enzyme activities, which are determined by
specialized techniques such as thin-layer chromatography
(TLC) and fluorometric enzymatic assays, respectively,
using fresh or frozen tissues [42, 43]. The histopatho-
logical and ultrastructural findings demonstrate swollen
neurons filled with periodic acid-Schiff stain-positive stor-
age materials and osmiophilic membranous cytoplasmic
bodies in the lysosomes of neurons, respectively, but these
characteristics are not completely specific to these diseases
[8, 28, 30, 34]. Genetic tests can be used to directly diag-
nose the diseases, but they are limited to diseases for
which specific mutations have been identified [44–46].
Therefore, it is possible that a correct diagnosis has not
been established in many animal cases, as a result of the
partial absence or lack of specimens for biochemical,
histological, ultrastructural, or genetic examination.
The aim of the present study was to establish immu-
nohistochemical and immunofluorescent techniques for
the auxiliary diagnosis of canine and feline gangliosi-
doses using paraffin-embedded brain specimens, which
are often stored for a long time in veterinary diagnostic
laboratories worldwide.
Methods
Specimens
Stored paraffin-embedded cerebral cortex samples of
dogs and cats with GM1 or GM2 gangliosidosis were
used in this study. These cases occurred in different
parts of Japan and the original diagnosis was made using
specific genetic tests and biochemical analyses at the
Laboratory of Clinical Pathology, Joint Faculty of Veterin-
ary Medicine, Kagoshima University, which has been ex-
clusively supporting the diagnosis of inherited metabolic
diseases in animals in Japan. These animals included a 14-
month-old Shiba Inu with GM1 gangliosidosis diagnosed
in 2009, an 11-month-old domestic shorthair cat with
GM1 gangliosidosis diagnosed in 2004, a 20-month-old
Toy Poodle with GM2 gangliosidosis diagnosed in 2006,
and a 20-month-old domestic shorthair cat with GM2
gangliosidosis diagnosed in 2010. The diagnosis of these
animals was established using genetic and/or biochemical
tests reported previously [11, 43–45]. Stored paraffin-
embedded cerebral cortex samples of a dog and a cat
without any brain disease were also used as controls. Thin
sections at 4 μm were prepared from these paraffin-
embedded tissue blocks by standard method. These sec-
tions were stained with hematoxylin and eosin (HE) and
subjected to the immunohistochemical and immunofluor-
escent techniques described below. All experimental pro-
cedures and ethical issues involving animals and their
samples were approved by the the Animal Research Com-
mittee at Kagoshima University with the approval number
VM15041.
Immunohistochemical study
Each section was deparaffinized with xylene and rehy-
drated through a graded ethanol series. Antigen retrieval
was conducted by heating the sample in a 10 mM citrate
buffer (pH 6.0) in a microwave oven. Thereafter, the
samples were washed in deionized water, treated with
3 % hydrogen peroxide, and washed in 0.01 M
phosphate-buffered saline (PBS; pH 7.4). Blocking was
performed with 0.25 % casein in 0.01 M PBS and incu-
bated overnight at 4°C with the respective reagents.
For the detection of GM1 ganglioside, biotinylated
cholera toxin B subunit (1:1000; List Biological Laborator-
ies, Inc., Campbell, CA, USA) was used. For the detection
of GM2 ganglioside, mouse anti-GM2 ganglioside mono-
clonal IgM antibody (1:1000; Tokyo Chemical Industry,
Co., Ltd., Tokyo, Japan) was used as a primary antibody,
and biotinylated goat anti-mouse IgM antibody (1:200; Vec-
tor Laboratories, Inc., Burlingame, CA, USA) was used as a
secondary antibody. Subsequently, these sections were in-
cubated with peroxidase-labeled streptavidin (KPL, Kirke-
gaard & Perry Laboratories, Inc., Gaithersburg, MD, USA).
The immunoreactivity was detected by a 3,3′-diaminoben-
zidine (DAB) system using DAB Tablet (Merck KGaA,
Darmstadt, Germany) as a peroxidase substrate. The sec-
tions were counterstained with hematoxylin.
Immunofluorescent study
Each section was pretreated in the same way as de-
scribed above for immunohistochemistry. For the detec-
tion of GM1 ganglioside, biotinylated cholera toxin B
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subunit (1:500; List Biological Laboratories, Inc.) and Alexa
Fluor 488-conjugated streptavidin (1:1000; Life Technolo-
gies, Inc., Gaithersburg, MD, USA) were used. For the de-
tection of GM2 ganglioside, mouse anti-GM2 monoclonal
IgM antibody (1:500; Vector Laboratories, Inc.) was used as
a primary antibody, and Alexa Fluor 488-conjugated goat
anti-mouse IgM antibody (1:1000; Life Technologies, Inc.)
was used as a secondary antibody. Subsequently, these
sections were incubated with a 4′,6-diamidino-2-phenylin-
dole dihydrochloride (DAPI) solution (1:1000; Dojindo
Laboratories, Inc., Kumamoto, Japan) for nuclear staining.
The fluorescence was observed using a fluorescence mi-
croscopy (BX53-33-FL2, Olympus, Corp., Tokyo, Japan).
Results
Using the HE stain, cytoplasmic accumulation of pale to
eosinophilic granular materials in balloon-swollen neu-
rons was observed in the cerebral cortex samples of dogs
and cats previously diagnosed with GM1 or GM2 gang-
liosidosis (Fig. 1a–d), whereas there was no such abnor-
mal change observed in the samples of the control
animals (Fig. 1e and f).
Using the immunohistochemical technique for the
detection of GM1 ganglioside, the accumulated cytoplas-
mic materials were positively stained and mainly identi-
fied as GM1 ganglioside in cells of animals with
confirmed GM1 gangliosidosis (Fig. 2a and b). In ani-
mals with GM2 gangliosidosis, the accumulated cyto-
plasmic materials were very weakly positively stained in
a portion of the cells of the affected cat (Fig. 2c and d).
In the control animals, the cytoplasm in some normal-
shaped cells was also positively stained to indicate the
presence of GM1 ganglioside (Fig. 2e and f). The nuclei
of several cells were positively stained in a portion of the
samples such as in the case of feline GM2 gangliosidosis
and in both control animals (Fig. 2d–f ).
Using the immunohistochemical technique for the de-
tection of GM2 ganglioside, the accumulated cytoplas-
mic materials were positively stained and mainly
identified as GM2 ganglioside in the cells of animals
with GM2 gangliosidosis (Fig. 3c and d), whereas these
materials were not strongly stained in animals with
GM1 gangliosidosis (Fig. 3a and b). In the control ani-
mals, the cytoplasm in some normal-shaped cells was
also weakly stained using this method (Fig. 3e and f).
The nuclei of several cells were weakly positively stained
in a portion of the samples such as in the case of canine
GM1 gangliosidosis and in both control animals (Fig. 3a,
e and f ).
The results of the immunofluorescent technique were
almost identical to those of the immunohistochemical
technique. The accumulated materials in the swollen
neurons of animals with gangliosidoses were positively
stained and clearly identified as either GM1 or GM2
ganglioside by using the respective detection techniques
for each ganglioside (Figs. 4 and 5). The accumulated
materials in the neurons of animals with GM2 gangliosi-
dosis were very weakly stained using the technique for
GM1 ganglioside (Fig. 4c and d), and vice versa (Fig. 5a
and b). In the control animals, some cells showed
Fig. 1 Histopathological findings in animals affected and unaffected with gangliosidoses. Hematoxylin and eosin staining was performed on
paraffin-embedded sections of the cerebral cortex from the following animals: a dog (a) and a cat (b) affected with GM1 gangliosidosis; a dog (c)
and a cat (d) affected with GM2 gangliosidosis; an unaffected control dog (e) and cat (f). Bar = 50 μm
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Fig. 2 Immunohistochemical findings for the detection of GM1 ganglioside in animals affected and unaffected with gangliosidoses. The
immunohistochemical technique for the detection of GM1 ganglioside was performed on paraffin-embedded sections of the cerebral cortex from the
following animals: a dog (a) and a cat (b) affected with GM1 gangliosidosis; a dog (c) and a cat (d) affected with GM2 gangliosidosis; an unaffected
control dog (e) and cat (f). For the detection of GM1 ganglioside, biotinylated cholera toxin B subunit and peroxidase-labeled streptavidin
were used. The immunoreactivity was detected by 3,3′-diaminobenzidine as a peroxidase substrate. The sections were counterstained with
hematoxylin. Bar = 50 μm
Fig. 3 Immunohistochemical findings for the detection of GM2 ganglioside in animals affected and unaffected with gangliosidoses. The
immunohistochemical technique for the detection of GM2 ganglioside was performed on paraffin-embedded sections of the cerebral cortex from the
following animals: a dog (a) and a cat (b) affected with GM1 gangliosidosis; a dog (c) and a cat (d) affected with GM2 gangliosidosis; an unaffected
control dog (e) and cat (f). For the detection of GM2 ganglioside, mouse anti-GM2 ganglioside monocloncal IgM antibody was used as a primary
antibody, and biotinylated goat anti-mouse IgM antibody was used as a secondary antibody. Subsequently, these sections were incubated with
peroxidase-labeled streptavidin. The immunoreactivity was detected by 3,3′-diaminobenzidine as a peroxidase substrate. The sections were
counterstained with hematoxylin. Bar = 50 μm
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cytoplasm that was positively stained for GM1 and GM2
gangliosides (Figs. 4 and 5e and f). In addition, some of
the cells of a cat with GM2 gangliosidosis and both con-
trol animals showed positive staining of nuclei using the
technique for the detection of GM1 ganglioside
(Fig. 4d–f ). Some of the cells of a control cat showed
weakly positive staining of nuclei using the technique for
the detection of GM2 ganglioside (Fig. 5f ).
Discussion
Gangliosides are glycosphingolipids consisting of a
hydrophobic ceramide (N-acylsphingosine) and a hydro-
philic oligosaccharide chain bearing one or more N-acet-
ylneuraminic acid (silalic acid) residues, and are typical
components of the outer leaflet of the plasma mem-
branes of animal cells [2, 3]. GM1 and GM2 gangliosides
are present as the main glycolipids in neurons and are
likely to be involved in cell differentiation and cell–cell
interactions, but their specific physiological functions re-
main obscure. Therefore, developing techniques for the
detection of GM1 and GM2 gangliosides is important
not only for advancement in brain science but also for
the correct diagnosis of gangliosidoses, because the
intralysosomal accumulation of each ganglioside in neu-
rons is characteristic to either GM1 or GM2 gangliosi-
dosis. Therefore, in the past few decades, various
determination methods for the profiling, quantification,
or evaluation of gangliosides, including GM1 and GM2
gangliosides, in tissues, cultured cells, or extracellular
fluids have been reported. These methods include TLC
coupled with densitometric or immunochemical detec-
tion [43, 47], high-performance liquid chromatography
coupled with tandem mass spectrometric detection [48],
enzyme-linked immunosorbent assay [49], and matrix-
assisted laser desorption ionization time-of-flight mass
spectrometry [50].
The in situ detection of gangliosides in tissue sections
is also very important not only for diagnosis of the
diseases but also to obtain reliable information on their
tissue, cellular, and subcellular distributions [51]. Fur-
thermore, confirming that the histological detection of
GM1 and GM2 gangliosides is applicable to paraffin-
embedded specimens stored for a long period would also
be useful for the retrospective diagnosis of the diseases,
but very few studies have evaluated such in situ detec-
tion methods using long-term stored paraffin-embedded
specimens from canine and feline gangliosidoses. In the
present study, immunohistochemical and immunofluor-
escent techniques for the detection of GM1 and GM2
gangliosides were developed, and their application was
evaluated using canine and feline paraffin-embedded
specimens stored for 5 to 11 years. As a result, these
two techniques could clearly detect the presence of both
GM1 and GM2 gangliosides in neurons of the control
animals (Figs. 2, 3, 4 and 5e and f) as well as the accu-
mulation of either GM1 or GM2 ganglioside in neurons
Fig. 4 Immunofluorescent findings for the detection of GM1 ganglioside in animals affected and unaffected with gangliosidoses. The
immunofluorescent technique for the detection of GM1 ganglioside was performed on paraffin-embedded sections of the cerebral cortex from the
following animals: a dog (a) and a cat (b) affected with GM1 gangliosidosis; a dog (c) and a cat (d) affected with GM2 gangliosidosis; an unaffected
control dog (e) and cat (f). For the detection of GM1 ganglioside, biotinylated cholera toxin B subunit and Alexa Fluor 488-conjugated streptavidin
were used. Subsequently, these sections were incubated with 4′,6-diamidino-2-phenylindole dihydrochloride for nuclear staining. Bar = 30 μm
Kohyama et al. BMC Veterinary Research  (2016) 12:67 Page 5 of 8
of animals with diagnosed GM1 (Figs. 2, 3, 4 and 5a and b)
and GM2 gangliosidoses (Figs. 2, 3, 4 and 5c and d). These
data demonstrate that the two techniques are applicable to
the retrospective in situ detection of GM1 and GM2 gangli-
osides, and consequently to the auxiliary diagnosis of gang-
liosidoses in dogs and cats. However, gangliosides can be
accumulated as the secondary products without direct
link to the primary protein defect in some lysosomal
and a few non-lysosomal diseases [2, 52]. Therefore,
in cases in which the abnormal accumulation of each
ganglioside is found in swollen neurons, a definitive
diagnosis should ultimately be made using DNA ex-
tracted from the same paraffin-embedded specimen
via the identification of pathogenic mutation(s) in the
responsible genes: the GLB1 gene for GM1 gangliosi-
dosis and the HEXA, HEXB, and GM2A genes for
GM2 gangliosidosis.
Comparing the two techniques developed in the present
study, the immunofluorescent technique provided relatively
less histopathological information than the immunohisto-
chemical technique, due to the dark background when
using immunofluorescence. Therefore, the tissue, cellular,
and subcellular distributions of stained materials could not
be easily determined in the immunofluorescent technique;
however, this technique does have the advantage of requir-
ing a lower amount of reagents (nearly half) because of its
higher detection sensitivity compared to the immunohisto-
chemical technique.
In addition, in the experiments conducted to detect
GM1 and GM2 gangliosides, the nuclei were stained in
some specimens using both techniques. The positive
staining of the nuclei in some cells from affected and
control animals may result from the natural components
of GM1 and GM2 gangliosides because the nuclei of
neuronal cells in rat brain contain these gangliosides
[53]. However, this stain of the nucleus was easily differ-
entiated from the specific stain of cytoplasmic GM1 and
GM2 gangliosides when using the immunohistochemical
technique but not when using the immunofluorescent
technique, owing to the reduced morphological visibility.
Therefore, the simultaneous observation of HE-stained
cerebral tissues (Fig. 1) is necessary for accurate
judgment of the results, especially when using an im-
munofluorescent technique.
Conclusions
The immunohistochemical and immunofluorescent
techniques for the detection of GM1 and GM2 ganglio-
sides established in this study are useful for the auxiliary
diagnosis of GM1 and GM2 gangliosidoses in dogs and
cats before a definitive diagnosis can be made using mo-
lecular analysis for identification of causative mutations.
Fig. 5 Immunofluorescent findings for the detection of GM2 ganglioside in animals affected and unaffected with gangliosidoses. The
immunofluorescent technique for the detection of GM2 ganglioside was performed on paraffin-embedded sections of the cerebral cortex from the
following animals: a dog (a) and a cat (b) affected with GM1 gangliosidosis; a dog (c) and a cat (d) affected with GM2 gangliosidosis; an unaffected
control dog (e) and cat (f). For the detection of GM2 ganglioside, mouse anti-GM2 monoclonal IgM antibody was used as a primary antibody, and
Alexa Fluor 488-conjugated goat anti-mouse IgM antibody was used as a secondary antibody. Subsequently, these sections were incubated with 4′,6-
diamidino-2-phenylindole dihydrochloride for nuclear staining. Bar = 30 μm
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These techniques may also be useful for the retrospect-
ive diagnosis of suspected cases of all animal species for
which paraffin-embedded cerebral tissues are stored.
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